We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Backs BMS’s Opdivo-Yervoy Combination Treatment
The UK’s drug pricing watchdog is recommending reimbursement of Bristol-Myers Squibb’s melanoma combination treatment of Opdivo and Yervoy, provided the company discounts the latter.